Healthcare >> CEO Interviews >> September 13, 2002
CHRISTOPHER KUEBLER, as the Chairman and Chief Executive Officer of
Covance, Inc., spearheaded the company's spin-off from Corning
Incorporated in January of 1997 and created one of the world's largest
and most comprehensive contract drug development services companies. Mr.
Kuebler joined Covance, formerly Corning Pharmaceutical Services, as the
company's President and Chief Executive Officer in 1994. Under Mr.
Kuebler's leadership, the company has expanded geographically and
operationally, enhanced its capabilities and integrated its businesses
around the world. Today, Covance offers its clients a broad array of
services at points throughout the entire drug development process ' from
preclinical testing through clinical trials management and periapproval
studies. Prior to joining Covance, Mr. Kuebler spent nearly 20 years in
the pharmaceutical industry. From 1985 to 1994 he held positions of
increasing responsibility at Abbott Laboratories in the company's
domestic pharmaceutical division, including Business Unit Director, Vice
President of Marketing and Vice President of Marketing and Sales. During
his last two years at Abbott, he served as Corporate Vice President of
Abbott Europe. Mr. Kuebler began his career in the pharmaceutical
industry in 1975 in various sales and marketing management positions for
E.R. Squibb and Sons, now part of Bristol-Myers Squibb. From 1984 to
1985, he worked at Monsanto Health Care as part of the company's
pharmaceutical acquisition team. Mr. Kuebler has served as a board
member of the National Pharmaceutical Council, and a member of the
Pharmaceutical Research and Manufacturers Association Marketing Steering
Committee. He also served as a member of the advisory committee of PNC
Bancorp. Mr. Kuebler, 47, holds a Bachelor of Science degree in
Biological Science from Florida State University. A resident of
Pennsylvania, he is married and has three daughters. Profile
on the company since we last spoke?
Mr. Kuebler: Covance is one of the world's leading comprehensive drug
development
